JKB-122 is effective, alone or in combination with prednisolone in Con A-induced hepatitis

Area of Science:

• Immunology
• Hepatology
• Pharmacology

Background:

• Autoimmune hepatitis (AIH) is a severe liver disease.
• Concanavalin A (Con A)-induced hepatitis in mice serves as a standard model for AIH.
• Toll-like receptor 4 (TLR4) plays a role in inflammatory liver injury.

Purpose of the Study:

• To evaluate the hepatoprotective activity of JKB-122, a TLR4 antagonist, in a Con A-induced hepatitis mouse model.
• To determine the efficacy of JKB-122 in mitigating liver damage and inflammation.
• To assess JKB-122's potential as a therapeutic agent for AIH.

Main Methods:

• Mice were challenged with Con A (15 mg/kg intravenously) to induce hepatitis.
• JKB-122 was administered at various time points and doses (20 and 50 mg/kg orally).
• Serum liver enzymes, liver pathology, and cytokine levels (IFN-γ, IL-1β, IL-4, IL-5, IL-6, IL-17A, TNF-α) were assessed at different time points post-challenge.

Main Results:

• JKB-122 administration dose-dependently reduced serum liver enzymes by up to 95% at 24 hours post-Con A challenge.
• JKB-122 significantly inhibited Con A-induced liver lesions and pro-inflammatory cytokine production as early as 3 hours post-challenge.
• Concurrent administration of JKB-122 with Con A showed similar protective effects.
• JKB-122 enhanced the efficacy of prednisolone in reducing liver lesions.

Conclusions:

• JKB-122 exhibits significant dose-dependent hepatoprotective activity in a mouse model of autoimmune hepatitis.
• The findings suggest that JKB-122 may be a promising therapeutic agent for AIH, both as a monotherapy and in combination with prednisolone.